Comparative evaluation of cytotoxic and anti-metastatic function of microbial chondroitin sulfate and animal-originated commercial chondroitin sulfate in cancer cells

Creative Commons License


Cellular and Molecular Biology, vol.69, no.9, pp.8-14, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 9
  • Publication Date: 2023
  • Doi Number: 10.14715/cmb/2023.69.9.2
  • Journal Name: Cellular and Molecular Biology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.8-14
  • Keywords: Animal-originated Chondroitin Sulfate, anti-metastatic agent, anticancer agent, Microbial Chondroitin Sulfate, wound healing
  • Karadeniz Technical University Affiliated: Yes


Cancer has the second-highest mortality rate worldwide after cardiovascular disease. In addition, cervical and breast cancer are two of the leading causes of cancer-related deaths among women. The tumor microenvironment, which consists of cells that form blood vessels, proteins, fibroblasts, and immune cells, is a therapeutic target for cancer therapy. As part of the extracellular matrix (ECM), glycosaminoglycan Chondroitin Sulfate (CS) is related to diverse aspects of tumor growth and metastasis depending on the CS sulfate pattern. This study analyzed the roles of Microbial CS and Commercial CS in tumor growth and metastasis using HeLa cervical cancer cells, MDA-MB-231 metastatic breast cancer cells, and normal fibroblasts. In addition, the role of CS types in wound healing was also assessed comparatively. Microbial CS was more cytotoxic in MDA-MB-231 cells than HeLa compared to Commercial CS. Although both CS reduced cell viability in normal cells, the selective index of Microbial CS in MDA-MB-213 cells was higher than its commercial counterpart. In addition, the role of CS types in wound healing was also assessed comparatively. Both types of CS decreased the cell migration in MDA-MB-231 breast cancer cells, but HeLa cells were more sensitive to Microbial CS than Commercial CS to heal the wound. The wound healing of NIH3T3 cells after Microbial CS was similarly high to the healing after Commercial CS. This preliminary study shows that microbial CS produced by biotechnological methods from a recombinant source created by our team can be an effective therapeutic agent in various types of cancer.